A federal jury Thursday announced a verdict favouring Ariad Pharmaceuticals in its patent infringement suit against Eli Lily & Co. A district court in Boston awarded Ariad Pharmaceuticals, the Massachusetts Institute of Technology, the Harvard University and the Whitehead Institute for Biomedical Research compensation worth $65.2 million. Cambridge, Massachusetts-based Ariad Pharmaceuticals had accused Eli Lily of infringing its patent covering any medical treatment targeting the human body’s molecular pathway. Ariad Pharmaceuticals said Eli Lily’s osteoporosis drug, Evista, and septic shock drug, Xigris, interact with a naturally occurring protein, NF-KB, in the human body. Eli Lily had in turn argued that Ariad Pharmaceuticals’ patent was invalid, since it covered a naturally occurring phenomenon.

Posted by GEN-ERIC at 02:41:47 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/678

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)